Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma

  • Authors:
    • Marileda Indinnimeo
    • Claudia Cicchini
    • Enrico Giarnieri
    • Alessandro Stazi
    • Pietro Luigi Mingazzini
    • Vincenzo Stipa
  • View Affiliations

  • Published online on: November 1, 2003     https://doi.org/10.3892/or.10.6.1875
  • Pages: 1875-1877
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although relatively little is known about the molecular mechanisms underlying tumor progression, recently CD44 glycoproteins and the c-Met receptor tyrosine kinase have been identified as potentially inportant components of the metastatic cascade. CD44 is a family of transmembrane receptors generated from a single gene by alternative splicing and differential glycosylation. Important biological processes involving CD44 glycoproteins include cell adhesion, lymphocyte homing, hematopoiesis, tumor progression and metastasis. The precise mechanism via which CD44 promotes tumorigenesis have not yet been elucidated. We evaluated the expression of adhesion molecule CD44 variant 6 in pulmonary metastases from colorectal carcinomas and its correlation with clinicopathological parameters. Twenty patients were randomly selected from the patients who had undergone a resection of pulmonary metastasis from colorectal cancer. Formalin-fixed, paraffin-embedded archival specimens of tumor tissues and adjacent normal mucosa from these patients were the subjects of the present study. Immunoreactivity for CD44 was quantified. Specimens were considered positive if almost 25% of the neoplastic cells were stained. CD44 v6 expression was related to the interval between colon resection and metastases diagnosis, the number of pulmonary metastases, and the survival after lung resection. No statistical correlation was found between CD44 v6 positivity and disease-free interval after colon resection, number of metastases or 2-year survival after lung resection. Probably CD44 v6 is necessary and sufficient to confer metastatic potential to carcinoma cells increasing the migration capacity and participating in invasion via changes in adhesion to the extracellular ligands, but is not necessary to modify the clinical history of the metastases. Therefore the evaluation of CD44 v6 expression in lung metastases does not influence the therapeutic scheme.

Related Articles

Journal Cover

November-December 2003
Volume 10 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Indinnimeo M, Cicchini C, Giarnieri E, Stazi A, Mingazzini PL and Stipa V: Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncol Rep 10: 1875-1877, 2003
APA
Indinnimeo, M., Cicchini, C., Giarnieri, E., Stazi, A., Mingazzini, P.L., & Stipa, V. (2003). Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncology Reports, 10, 1875-1877. https://doi.org/10.3892/or.10.6.1875
MLA
Indinnimeo, M., Cicchini, C., Giarnieri, E., Stazi, A., Mingazzini, P. L., Stipa, V."Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma". Oncology Reports 10.6 (2003): 1875-1877.
Chicago
Indinnimeo, M., Cicchini, C., Giarnieri, E., Stazi, A., Mingazzini, P. L., Stipa, V."Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma". Oncology Reports 10, no. 6 (2003): 1875-1877. https://doi.org/10.3892/or.10.6.1875